Skip to main content
Surrozen, Inc./DE logo

Surrozen, Inc./DE — Investor Relations & Filings

Ticker · SRZN ISIN · KYG2445M1033 US Professional, scientific and technical activities
Open in API
Filings indexed 447 across all filing types
Latest filing 2026-05-14 Declaration of Voting R…
Country US United States of America
Listing US SRZN

About Surrozen, Inc./DE

https://www.surrozen.com

Surrozen, Inc. is a clinical-stage company that discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is pioneering a new class of targeted regenerative antibodies designed to stimulate the body's own repair mechanisms. These therapeutics aim to repair a broad range of tissues and restore organs damaged by serious diseases and injuries, with the goal of unlocking the body's regenerative power.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K “Current Report” filed under Item 5.07 “Submission of Matters to a Vote of Security Holders.” It provides detailed voting results from the 2026 Annual Meeting of Stockholders, including tally of shares for director elections, ratification of auditors, and advisory votes on executive compensation. This aligns exactly with the category for official results of shareholder votes, i.e., Declaration of Voting Results & Voting Rights Announcements.
2026-05-14 English
ARS - Surrozen, Inc./DE (0001824893) (Filer)
Annual Report
2026-04-01 English
DEF 14A - Surrozen, Inc./DE (0001824893) (Filer)
Proxy Solicitation & Information Statement
2026-04-01 English
4 - Surrozen, Inc./DE (0001824893) (Issuer)
Director's Dealing
2026-03-26 English
S-8 - Surrozen, Inc./DE (0001824893) (Filer)
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 filing, which is a registration statement used by companies to register securities to be offered under employee benefit plans such as stock option plans or employee stock purchase plans. The text includes detailed tables calculating the filing fee for newly registered securities under the 2021 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan. It references the Securities Act of 1933 and Rule 416(a), and provides specific data on shares, prices, and fees. This type of filing is related to share issuance and registration of securities for employee plans, not a financial report, management announcement, or other categories. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length (5584 characters) and content confirm it is the actual filing, not just an announcement or certification.
2026-03-23 English
S-3 - Surrozen, Inc./DE (0001824893) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a detailed calculation of filing fees related to a Form S-3 registration statement for securities offerings by Surrozen, Inc. It includes tables specifying security types, fee calculations, and fee offsets. The presence of Form S-3 and detailed fee tables indicates this is a capital raising or securities registration filing. There is no financial performance data, management discussion, or earnings information. The document is not an announcement of a report but a regulatory filing related to securities registration and fees. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-03-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.